This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially available Closed-Loop Control (CLC) System (Control-IQ Technology).
1 Primary · 4 Secondary · Reporting Duration: 4 weeks
Active Control
90 Total Participants · 2 Treatment Groups
Primary Treatment: CLC, then CLC+BAM, then CLC+ABC · No Placebo Group · N/A
Age 18 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: